A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dolastatin-10 (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- 06 Mar 2014 Biomarkers information updated
- 10 Sep 2005 New trial record.